Literature DB >> 31709168

Visualized oncoplastic surgery of the breast I: inferior and medial quadrantectomy.

Alberto Rancati1, Claudio Angrigiani1, Julio Dorr1, Marcelo Irigo1, Maurizio B Nava2,3, Giuseppe Catanuto3,4, Nicola Rocco3,5, Agustin Rancati1.   

Abstract

Surgical treatment of breast cancer has changed during the last few decades. Long-term evaluation of several studies performed worldwide have confirmed that conservative surgery (CS) and radical mastectomy have similar survival rates. Due to CS being the gold standard for treatment for most women with breast cancer, advances in materials, mastectomy and reconstructive surgery techniques, now give us the possibility to perform on our patients a great outcome with oncological security. Both advances, in plastic and oncologic surgery, created a new discipline, called oncoplastic breast surgery, that allow surgeons to resect large breast specimens preventing subsequent deformities with the correct previous planning. This is particularly important when more than 30% of the breast volume will be resected because it allows for planning CS depending on the site of the lesion and for establishing the limits between CS and mastectomy. 2019 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Superior pedicle; oncoplastic; quadrantectomy

Year:  2019        PMID: 31709168      PMCID: PMC6819890          DOI: 10.21037/gs.2019.04.02

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  21 in total

1.  [Reduction mammaplasty in breast cancer surgery].

Authors:  Fernando Hernanz De La Fuente; Manuel Gómez Fleitas; Francisco Martínez García
Journal:  Cir Esp       Date:  2009-03-05       Impact factor: 1.653

2.  Oncoplastic options in breast conservative surgery.

Authors:  Alberto Rancati; Eduardo Gonzalez; Claudio Angrigiani; Gustavo Gercovich; Ernesto Gil Deza; Julio Dorr
Journal:  Gland Surg       Date:  2013-08

3.  Oncoplastic surgery in breast conservation: a prospective evaluation of the patients, techniques, and oncologic outcomes.

Authors:  Ahmad Kaviani; Amin Safavi; Narjes Mohammadzadeh; Khatereh Jamei; Maryam Ansari-Damavandi; Remy J Salmon
Journal:  Am J Surg       Date:  2014-06-20       Impact factor: 2.565

Review 4.  Management of the Ischemic Nipple-Areola Complex After Breast Reduction.

Authors:  Alberto Rancati; Marcelo Irigo; Claudio Angrigiani
Journal:  Clin Plast Surg       Date:  2016-02-03       Impact factor: 2.017

5.  Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery.

Authors:  Krishna B Clough; Gabriel J Kaufman; Claude Nos; Ines Buccimazza; Isabelle M Sarfati
Journal:  Ann Surg Oncol       Date:  2010-02-06       Impact factor: 5.344

6.  Clinical series of oncoplastic mastopexy to optimize cosmesis of large-volume resections for breast conservation.

Authors:  J Bong; J Parker; R Clapper; W Dooley
Journal:  Ann Surg Oncol       Date:  2010-06-12       Impact factor: 5.344

7.  An outcome study of breast reconstruction: presurgical identification of risk factors for complications.

Authors:  K Y Lin; F R Johns; J Gibson; M Long; D B Drake; M M Moore
Journal:  Ann Surg Oncol       Date:  2001-08       Impact factor: 5.344

8.  Cosmesis with bilateral mammoreduction for conservative breast cancer treatment.

Authors:  Thomas E Goffman; Heather Schneider; Karen Hay; David E Elkins; Robert A Schnarrs; Claire Carman
Journal:  Breast J       Date:  2005 May-Jun       Impact factor: 2.431

9.  Bilateral reduction mammoplasty in combination with lumpectomy for treatment of breast cancer in patients with macromastia.

Authors:  Eugene Chang; Nathalie Johnson; Bruce Webber; James Booth; Dina Rahhal; David Gannett; William Johnson; Daisy Franzini; Henry Zegzula
Journal:  Am J Surg       Date:  2004-05       Impact factor: 2.565

10.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.